Pitié-Salpêtrière Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (35)

2016

  1. Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation

    Acta Neuropathologica Communications, Vol. 4, Núm. 1

  2. Sorting the good from the bad: The different approaches to predict cognitive properties of new symptomatic drug candidates for neurodegenerative diseases in early development

    CNS and Neurological Disorders - Drug Targets

2015

  1. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with alzheimer-like Tau pathology

    Human Molecular Genetics, Vol. 24, Núm. 21, pp. 5965-5976

2013

  1. Evaluation of symptomatic drug effects in Alzheimer's disease: Strategies for prediction of efficacy in humans

    Drug Discovery Today: Technologies, Vol. 10, Núm. 3

2012

  1. Clinical, neuropathological, and biochemical characterization of the novel tau mutation P332S

    Journal of Alzheimer's Disease, Vol. 31, Núm. 4, pp. 741-749

2011

  1. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, Núm. 16, pp. 6632-6637

2009

  1. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication

    Journal of Neurochemistry, Vol. 110, Núm. 4, pp. 1321-1329

2008

  1. Increased mRNA expression of cytochrome oxidase in dorsal raphe nucleus of depressive suicide victims

    Neuropsychiatric Disease and Treatment, Vol. 4, Núm. 2, pp. 413-416

2007

  1. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism

    Brain, Vol. 130, Núm. 1, pp. 265-275

2005

  1. Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian

    Journal of Neural Transmission, Vol. 112, Núm. 9, pp. 1237-1248

2004

  1. Blood vessels and parkinsonism

    Frontiers in Bioscience, Vol. 9, pp. 277-282

  2. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure

    GLIA, Vol. 46, Núm. 4, pp. 402-409

2000

  1. Metabolic effects of nigrostriatal denervation in basal ganglia

    Trends in Neurosciences, Vol. 23, Núm. 10 SUPPL.

1998

  1. [125I]EGF binding in basal ganglia of patients with Parkinson's disease and progressive supranuclear palsy and in MPTP-treated monkeys

    Experimental Neurology, Vol. 154, Núm. 1, pp. 146-156

1997

  1. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: An in situ hybridization study of cytochrome oxidase subunit I mRNA

    Journal of Neuroscience, Vol. 17, Núm. 2, pp. 765-773

  2. Expression of Bcl-2 in adult human brain regions with special reference to neurodegenerative disorders

    Journal of Neurochemistry, Vol. 69, Núm. 1, pp. 223-231

  3. Neurochemical correlates of parkinsonism. Role of dopaminergic lesions.

    Advances in neurology, Vol. 74, pp. 119-126

  4. Re-evaluation of the functional anatomy of the basal ganglia. In normal and Parkinsonian states

    Neuroscience

1996

  1. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum

    Neurology, Vol. 47, Núm. 1, pp. 219-224

  2. Consequences of nigrostriatal denervation on the γ-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes

    Neurology, Vol. 46, Núm. 3, pp. 802-809